Update on the Treatment of Metastatic Urothelial Carcinoma
Platinum-based combination chemotherapy has been the standard of care in the first-line treatment of metastatic urothelial carcinoma (mUC). Treatment of metastatic disease following progression on platinum-based regimens has evolved significantly in the last few years. Clinical trials are currently...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2018/5682078 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558753426178048 |
|---|---|
| author | Nedal Bukhari Humaid O. Al-Shamsi Faisal Azam |
| author_facet | Nedal Bukhari Humaid O. Al-Shamsi Faisal Azam |
| author_sort | Nedal Bukhari |
| collection | DOAJ |
| description | Platinum-based combination chemotherapy has been the standard of care in the first-line treatment of metastatic urothelial carcinoma (mUC). Treatment of metastatic disease following progression on platinum-based regimens has evolved significantly in the last few years. Clinical trials are currently ongoing to determine how best to use and sequence these treatments. In this minireview, we will review current first-line treatment options in both cisplatin fit and cisplatin unfit patients and advances in first- and second-line treatments including chemotherapy and immunotherapy. This review reports key findings from the clinical trials especially highlighting the importance of PD-1 and PD-L1 inhibitors in the treatment of bladder/urothelial carcinomas. |
| format | Article |
| id | doaj-art-c5212b1592f84220af31be3373259515 |
| institution | Kabale University |
| issn | 2356-6140 1537-744X |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-c5212b1592f84220af31be33732595152025-02-03T01:31:44ZengWileyThe Scientific World Journal2356-61401537-744X2018-01-01201810.1155/2018/56820785682078Update on the Treatment of Metastatic Urothelial CarcinomaNedal Bukhari0Humaid O. Al-Shamsi1Faisal Azam2Department of Medical Oncology, King Fahad Specialist Hospital Dammam, Dammam, Saudi ArabiaAssociate Professor, University of Sharjah, Sharjah, UAEDepartment of Medical Oncology, King Fahad Specialist Hospital Dammam, Dammam, Saudi ArabiaPlatinum-based combination chemotherapy has been the standard of care in the first-line treatment of metastatic urothelial carcinoma (mUC). Treatment of metastatic disease following progression on platinum-based regimens has evolved significantly in the last few years. Clinical trials are currently ongoing to determine how best to use and sequence these treatments. In this minireview, we will review current first-line treatment options in both cisplatin fit and cisplatin unfit patients and advances in first- and second-line treatments including chemotherapy and immunotherapy. This review reports key findings from the clinical trials especially highlighting the importance of PD-1 and PD-L1 inhibitors in the treatment of bladder/urothelial carcinomas.http://dx.doi.org/10.1155/2018/5682078 |
| spellingShingle | Nedal Bukhari Humaid O. Al-Shamsi Faisal Azam Update on the Treatment of Metastatic Urothelial Carcinoma The Scientific World Journal |
| title | Update on the Treatment of Metastatic Urothelial Carcinoma |
| title_full | Update on the Treatment of Metastatic Urothelial Carcinoma |
| title_fullStr | Update on the Treatment of Metastatic Urothelial Carcinoma |
| title_full_unstemmed | Update on the Treatment of Metastatic Urothelial Carcinoma |
| title_short | Update on the Treatment of Metastatic Urothelial Carcinoma |
| title_sort | update on the treatment of metastatic urothelial carcinoma |
| url | http://dx.doi.org/10.1155/2018/5682078 |
| work_keys_str_mv | AT nedalbukhari updateonthetreatmentofmetastaticurothelialcarcinoma AT humaidoalshamsi updateonthetreatmentofmetastaticurothelialcarcinoma AT faisalazam updateonthetreatmentofmetastaticurothelialcarcinoma |